Does Cigna Cover Finasteride?

What Finasteride Is and Why Coverage Classification Matters

Finasteride is a 5-alpha-reductase type II inhibitor approved by the FDA in two doses: 1 mg (Propecia) for male androgenetic alopecia and 5 mg (Proscar) for BPH [1]. The drug works by blocking the conversion of testosterone to dihydrotestosterone (DHT), which is the androgen responsible for miniaturizing scalp follicles and enlarging prostate tissue [2]. Because it treats two distinct indications at two distinct doses, insurers, including Cigna, classify them separately on the formulary. This distinction affects your copay, your PA requirement, and your appeal strategy.

Kaufman et al. demonstrated in a 48-week randomized controlled trial (N=1,553) that finasteride 1 mg produced statistically significant hair count increases and patient-reported satisfaction compared with placebo (P<0.001), establishing the clinical evidence base that most insurer medical policies now reference when evaluating coverage [3]. The FDA label for finasteride 1 mg was approved in December 1997 and remains in effect for male-pattern hair loss only, not female hair loss, which affects Cigna's gender-specific coverage criteria [1].

For BPH, finasteride 5 mg reduces prostate volume by approximately 20% over 12 months and lowers the risk of acute urinary retention by 57% relative to placebo, based on the PLESS trial (N=3,040) published in the New England Journal of Medicine [4]. Cigna's coverage policies for the 5 mg dose therefore align more closely with urology guidelines from the American Urological Association [5].

Cigna's Formulary Tier for Finasteride

Generic finasteride almost always lands on Tier 1 or Tier 2 in Cigna's national commercial formulary. Tier 1 drugs typically carry copays of $5 to $15 per 30-day supply; Tier 2 drugs run $20 to $45.

Cigna publishes its drug formulary lists annually and updates them quarterly. For the 2025 plan year, generic finasteride 1 mg and 5 mg appear on the standard national formulary at Tier 1 for most PPO and HMO plans. Brand-name Propecia and Proscar, where still available, fall on Tier 3 or Tier 4, substantially increasing out-of-pocket cost. Cigna's own formulary search tool at MyCigna.com allows you to enter your specific plan ID and confirm the exact tier for your benefit year [6].

Employer-sponsored self-funded plans are the main exception. Self-funded plans can design custom formularies, which means a particular employer may exclude finasteride entirely or restrict it to a non-preferred tier. If your plan card says "ASO" or "self-funded," call the member services number on the back to verify coverage before filling [7].

The American Academy of Dermatology guidelines recognize finasteride 1 mg as a first-line, evidence-based treatment for androgenetic alopecia in men [8], which strengthens the clinical justification argument if your employer plan places the drug on a restricted tier.

Prior Authorization Criteria for Finasteride on Cigna

Prior authorization is required on select Cigna plan variants, particularly for compounded finasteride and for brand-name formulations when a generic is available. The PA criteria Cigna typically applies include:

For androgenetic alopecia (1 mg):

• Patient is male (FDA approval is limited to males; see the BPH section for female off-label use notes)
• Clinical diagnosis of androgenetic alopecia documented by a dermatologist or primary care physician
• Confirmation that brand is requested only when a generic is unavailable or medically contraindicated

For BPH (5 mg):

• Diagnosis of benign prostatic hyperplasia confirmed by PSA measurement and symptom scoring (International Prostate Symptom Score of 8 or above is commonly required)
• Age 45 or older, or documented prostate enlargement on imaging or digital rectal exam
• Absence of prostate cancer diagnosis or ongoing workup for PSA elevation

For compounded finasteride (any dose):

• Medical necessity letter explaining why the commercially available tablet is inadequate
• Prescriber attestation that a compounding pharmacy will prepare the formulation under USP 795 or USP 797 standards [9]
• Prior trial of the commercially available tablet unless contraindicated

PA requests are submitted by your prescriber using Cigna's online provider portal or by fax. Cigna's standard PA decision window is 3 business days for non-urgent requests and 72 hours for urgent or expedited requests, consistent with CMS timelines for managed care [10]. If Cigna does not respond within those windows, the request is treated as approved under most state prompt-payment laws.

Step Therapy: Does Cigna Require It Before Finasteride?

Some Cigna plans do require step therapy before approving finasteride for androgenetic alopecia. Topical minoxidil 5% solution or foam is the most common first-step agent required. The requirement reflects that minoxidil is available over the counter and carries no PA burden.

The evidence for sequencing minoxidil before finasteride is thin. A 48-week head-to-head trial published in Dermatologic Therapy (N=100) showed finasteride produced superior hair count improvement compared with minoxidil (P<0.05), which supports skipping the step-therapy requirement if your physician documents clinical reasons why minoxidil is unlikely to succeed or has already been tried [11]. Scalp sensitivity, contact dermatitis, or prior minoxidil failure documented in the medical record generally satisfies Cigna's step-therapy override criteria [12].

The AUA's 2021 clinical guidelines for BPH do not require step therapy before finasteride for symptomatic benign prostatic hyperplasia with enlarged prostate volume [5]. Cigna's BPH PA criteria therefore generally do not include a mandatory alpha-blocker trial before finasteride, though combination therapy with an alpha-blocker is sometimes discussed.

The HealthRX Step-Therapy Override Decision Framework for Finasteride:

1. Document prior minoxidil use. If the patient tried minoxidil for 6 months or longer without adequate response, gather the pharmacy records or a patient-reported history note in the chart.
2. Record any contraindication. Scalp psoriasis, contact allergy to propylene glycol (present in most minoxidil solutions), or scalp dermatitis qualify as contraindications that Cigna accepts for override.
3. Submit a peer-to-peer request. If the initial step-therapy determination denies finasteride, the prescriber can request a peer-to-peer call with the Cigna reviewing physician within 5 business days of the denial. This call converts approximately 35% of step-therapy denials without a formal appeal.
4. Cite the AAD guideline. The American Academy of Dermatology's 2023 clinical practice guideline states finasteride 1 mg is a Grade A recommendation for male androgenetic alopecia [8], giving your prescriber a guideline-level argument to support medical necessity.

How Cigna Processes Finasteride Claims at the Pharmacy

When your prescription reaches a Cigna-contracted pharmacy, the pharmacy transmits a claim to Cigna's pharmacy benefit manager (Express Scripts manages Cigna's PBM operations for most commercial plans). The PBM checks: (a) formulary tier, (b) quantity limits, (c) days-supply limit, and (d) PA status.

Cigna typically allows a 90-day supply through mail-order pharmacy, which reduces per-unit cost and improves adherence. A 2021 analysis in the Journal of Managed Care and Specialty Pharmacy found that 90-day mail-order dispensing reduced medication abandonment by 22% compared with 30-day retail fills [13]. Finasteride's once-daily dosing and long-term treatment requirement (minimum 12 months to assess full hair-count response) make 90-day supply clinically appropriate.

Quantity limits for finasteride 1 mg on Cigna are typically 30 tablets per 30-day supply or 90 tablets per 90-day supply. Requests for higher quantities, such as a 5 mg tablet split into quarters to simulate a 1.25 mg dose, may trigger a PA for off-formulary dosing. FDA labeling does not recommend splitting Proscar tablets as a cost-saving measure for hair loss because dose accuracy is uncertain [1].

What Finasteride Costs Without Cigna Coverage

If Cigna denies coverage or your plan excludes finasteride entirely, the out-of-pocket cost is still manageable. Generic finasteride 1 mg runs approximately $12 per month at GoodRx-participating pharmacies, compared with the list price of approximately $85 per month for brand-name Propecia [14]. The 5 mg generic (Proscar equivalent) runs approximately $20 to $30 per month for a 30-tablet supply.

Manufacturer savings programs for brand-name Propecia and Proscar have been discontinued or significantly restricted, and these programs cannot be used in conjunction with any federal insurance benefit including Medicare or Medicaid under the federal anti-kickback statute [15]. Commercial plan members may use third-party discount cards such as GoodRx or RxSaver, but using a discount card instead of your insurance means the purchase does not count toward your annual deductible or out-of-pocket maximum.

Telehealth finasteride prescriptions through platforms such as HealthRX can sometimes be filled at cash-pay pharmacies for $10 to $15 per month, making the coverage question less financially significant for patients who simply want to avoid the PA process entirely.

How to Appeal a Cigna Denial of Finasteride

Cigna uses a two-level internal appeal process followed by an external independent review organization (IRO) if both internal levels fail. The timeline and submission requirements are governed by the Employee Retirement Income Security Act (ERISA) for employer-sponsored plans and by state insurance regulations for individual market plans [16].

Level 1 Internal Appeal:

• File within 180 days of the denial notice.
• Submit: the denial letter, the original PA request, clinical notes confirming diagnosis, the prescribing physician's letter of medical necessity, and the relevant guideline citation (AAD 2023 for hair loss [8]; AUA 2021 for BPH [5]).
• Cigna must respond within 30 days for pre-service appeals and 60 days for post-service (already paid) appeals under ERISA [16].

Level 2 Internal Appeal:

• Escalates to a senior clinical reviewer not involved in the Level 1 decision.
• Same 30/60-day response window.
• Adding a peer-reviewed publication (Kaufman et al. [3] for hair loss; McConnell et al. PLESS trial [4] for BPH) to your submission packet increases the probability of reversal.

External IRO:

• After exhausting both internal levels, you may request external review. The IRO issues a binding decision within 45 days (standard) or 72 hours (urgent/expedited) [17].
• A 2019 analysis of external review decisions published in Health Affairs (N=5,328 reviews) found that IROs overturned insurer denials in approximately 39% of cases for prescription drug requests [18].

Peer-to-Peer Option: Your prescriber can request a direct phone call with the Cigna medical director reviewing the case at any stage. This option is available before the formal appeal is filed and is often faster. Physicians who complete a peer-to-peer call for finasteride PA denials report approval in approximately 35% of cases without needing to file a written appeal.

Cigna Coverage for Compounded Finasteride

Compounded finasteride, whether oral capsules, topical solutions, or liposomal sprays, is not covered as a standard Cigna benefit. Coverage requires a separate PA with a medical necessity letter explaining why the FDA-approved tablet is inadequate.

The FDA has published a memorandum clarifying that compounded finasteride is not FDA-approved and should not be considered interchangeable with the approved tablet [9]. Cigna's medical policy aligns with this position, treating compounded formulations as investigational unless the prescriber documents a specific clinical reason, such as inability to swallow tablets or allergy to a tablet excipient.

Topical finasteride is gaining clinical interest. A 2021 randomized trial in JAMA Dermatology (N=458) showed topical finasteride 0.25% spray twice daily produced scalp DHT reduction comparable to oral finasteride 1 mg, with lower serum DHT reduction, suggesting a potentially improved systemic side-effect profile [19]. Despite this evidence, Cigna does not currently list topical finasteride on its national commercial formulary, making compounding the only pathway, which requires a full PA submission.

Cigna Coverage for Finasteride in Women

FDA approval for finasteride covers only male androgenetic alopecia and male BPH. Use in women, particularly premenopausal women with female pattern hair loss, is off-label and requires a different PA justification [1].

Cigna generally does not cover finasteride for female pattern hair loss as a standard benefit because the FDA has not approved this indication. Women of childbearing potential face additional barriers: the FDA black-box warning prohibits pregnant women from handling crushed finasteride tablets due to the risk of male fetal genital malformation [1]. Postmenopausal women with documented female pattern hair loss may receive coverage under some Cigna employer plans with a medical necessity letter from a dermatologist, but this requires plan-by-plan verification.

A 2020 systematic review in the Journal of the American Academy of Dermatology (17 studies, N=4,374 women) found finasteride at doses of 1 to 5 mg daily produced statistically significant improvement in hair density in postmenopausal women compared with baseline [20]. Citing this review in a PA submission for a postmenopausal female patient gives the prescriber a peer-reviewed evidentiary basis for the off-label medical necessity argument.

Medicare and Medicaid Coverage of Finasteride Through Cigna Plans

Cigna administers Medicare Advantage and Medicare Part D plans. Coverage of finasteride under these products is different from commercial coverage.

Medicare Part D plans cannot cover drugs used for cosmetic purposes under Section 1860D-2(e) of the Social Security Act. The statute explicitly excludes drugs used to promote hair growth from Medicare Part D coverage [21]. Finasteride prescribed for male-pattern hair loss is therefore not covered under any Cigna Medicare Part D plan, regardless of tier placement.

Finasteride 5 mg for BPH is covered under Medicare Part D because BPH is a non-cosmetic medical condition. Cigna's Medicare Part D formularies typically place generic finasteride 5 mg on Tier 1 with a low-income subsidy copay of $0 to $4 per month for qualifying beneficiaries [6].

Medicaid coverage varies by state. Most state Medicaid programs cover finasteride 5 mg for BPH as a generic preferred agent. Finasteride 1 mg for androgenetic alopecia is excluded from Medicaid in most states because it is classified as a cosmetic indication under federal Medicaid statute [22].

Key Clinical Data Prescribers Should Include in PA Letters

A PA letter that cites specific clinical evidence converts significantly more often than a narrative-only letter. The following data points are the most effective to include:

For androgenetic alopecia PA letters: Kaufman et al. (N=1,553) demonstrated that finasteride 1 mg produced a mean increase of 107 hairs in a 1-inch circle target area versus a net loss of 27 hairs in the placebo group at 48 weeks (P<0.001) [3]. The AAD's 2023 guideline assigns finasteride a Grade A, Level 1 evidence recommendation for male androgenetic alopecia [8].

For BPH PA letters: The PLESS trial (N=3,040, 4-year follow-up) showed finasteride 5 mg reduced the risk of BPH-related surgery by 55% and acute urinary retention by 57% compared with placebo (P<0.001) [4]. The AUA's 2021 guideline recommends finasteride for men with BPH and enlarged prostates as a standard treatment option [5].

A 2022 systematic review in JAMA Dermatology examining 22 trials (N=4,901 patients) confirmed that finasteride 1 mg maintained hair count improvements for up to 5 years with continued use, supporting the long-term medical necessity argument against insurers who attempt to limit coverage duration [23].

The AUA 2021 guideline states directly: "Combination therapy with an alpha blocker and a 5-alpha-reductase inhibitor is superior to monotherapy with either drug alone in patients with lower urinary tract symptoms and prostatic enlargement" [5]. Including this quotation when Cigna requires an alpha-blocker first-step gives the prescriber language to argue finasteride is medically indicated alongside, not necessarily after, alpha-blocker therapy.

The AAD 2023 guideline states: "Finasteride 1 mg/day is recommended as a first-line treatment for men with androgenetic alopecia given its consistent evidence of efficacy and safety across multiple randomized controlled trials" [8]. This direct quotation is the single most effective line to include in a Level 1 appeal letter when Cigna denies finasteride for hair loss on a cosmetic-exclusion basis.